Abstract

Background: Polycistic ovary syndrome (PCOs) is one of the most common endocrine and metabolic disorders in premenopausal women. This is the second part of an extended report regarding the significant effects of the therapy based on an Alfa Lipoic Acid (ALA)/Myoinositol (Myo) combined drug on adnexal parameters, as assessed by ultrasound technique. Methods: A prospective cohort trial. Data regarded thirty four italian nulliparous women considered for the study, control cases were chosen from an initial group of sixty-nine healthy women group paired by age and nulliparous status. Patients underwent a Myoinositol plus ALA regimen twice a day in a continued fashion in a twenty four months period. Ultrasound examinations were coincident with the fifth day of menstrual period and were set as follows: Time 0 (first evaluation), Time 12 (after twelve months) and finally Time 24 (after 24 months). Results: The mean age was 31.4 years old. Results regarding any significant change in the endometrial width, number of follicles, and the ovarian volumes within the time of the trial, showed no significant changes in the intervals considered. Conversely, the parameters dealing with color Doppler velocimetry waves of the ovarian arteries showed a significant decreasing trend, considering the first values and after 12 and 24 months. Conclusions: Considering a consistent and significant decrease in ovarian arteries resistance, we may hypothesize that Inositol plus ALA therapy may block the vascular effects of hyperadrogenism, maybe playing a role in the anti oxidant and anti inflammatory pathways

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.